0001209191-20-046871.txt : 20200814 0001209191-20-046871.hdr.sgml : 20200814 20200814210009 ACCESSION NUMBER: 0001209191-20-046871 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200806 FILED AS OF DATE: 20200814 DATE AS OF CHANGE: 20200814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOBULSKY SUSAN CENTRAL INDEX KEY: 0001820885 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 201107772 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-08-06 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001820885 BOBULSKY SUSAN C/O ADAPTIVE BIOTECHNOLOGIES CORP. 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 0 1 0 0 SVP, Diagnostics, clonoSEQ Stock Option (Right to Buy) 1.98 2024-10-13 Common Stock 65000 D Stock Option (Right to Buy) 6.27 2027-04-25 Common Stock 20000 D Stock Option (Right to Buy) 6.55 2028-04-24 Common Stock 28750 D Stock Option (Right to Buy) 28.32 2030-02-27 Common Stock 13474 D All options are fully exercisable. The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on April 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Susan Bobulsky by Eric Billings, Attorney-in-fact 2020-08-14 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

LIMITED POWER OF ATTORNEY
FOR SECTION 16(a) REPORTING

	KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes,
constitutes and appoints Chad Cohen, Kyle Piskel and Eric Billings as the
undersigned's true and lawful attorney-in-fact (the "Attorney-in-Fact"), with
full power of substitution and resubstitution, each with the power to act alone
for the undersigned and in the undersigned's name, place and stead, in any and
all capacities to:

	1.	Prepare, execute, deliver and file with the United States Securities and
Exchange Commission, any national securities exchange and Adaptive
Biotechnologies Corporation (the "Company") any and all reports (including any
amendment thereto) of the undersigned required or considered advisable under
Section 16(a) of the Exchange Act, and the rules and regulations thereunder,
with respect to the equity securities of the Company, including Form 3 (Initial
Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes
in Beneficial Ownership), and Form 5 (Annual Statement of Changes in Beneficial
Ownership); and

	2.	Seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information on transactions in the Company's equity
securities from any third party, including the Company, brokers, dealers,
employee benefit plan administrators and trustees, and the undersigned hereby
authorizes any such third party to release any such information to the Attorney-
in-Fact.

	The undersigned acknowledges that:

	1.	This Limited Power of Attorney authorizes, but does not require, the
Attorney-in-Fact to act at his or her discretion on information provided to such
Attorney-in-Fact without independent verification of such information;

	2.	Any documents prepared and/or executed by the Attorney-in-Fact on behalf
of the undersigned pursuant to this Limited Power of Attorney will be in such
form and will contain such information as the Attorney-in-Fact, in his or her
discretion, deems necessary or desirable;

	3.	Neither the Company nor the Attorney-in-Fact assumes any liability for
the undersigned's responsibility to comply with the requirements of Section 16
of the Exchange Act, any liability of the undersigned for any failure to comply
with such requirements, or any liability of the undersigned for disgorgement of
profits under Section 16(b) of the Exchange Act; and

	4.	This Limited Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigned's obligations under Section
16 of the Exchange Act, including, without, limitation, the reporting
requirements under Section 16(a) of the Exchange Act.

	The undersigned hereby grants to the Attorney-in-Fact full power and
authority to do and perform each and every act and thing requisite, necessary or
convenient to be done in connection with the foregoing, as fully, to all intents
and purposes, as the undersigned might or could do in person, hereby ratifying
and confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Limited
Power of Attorney.

	This Limited Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 or 5 with respect to
the undersigned's holdings of and transactions in equity securities of the
Company, and shall only be revoked upon the earliest of (i) revocation by the
undersigned in a signed writing delivered to the Attorney-in-Fact or to the
Secretary of the Company, (ii) termination of the undersigned's service as an
employee or director (as applicable) of the Company, (iii) termination of the
Attorney-in-Fact's service as an officer or other employee of the Company, or
(iv) execution of a subsequent power of attorney by the undersigned which
specifically provides for the revocation of any prior power of attorney
regarding reporting requirements under Section 16(a) of the Exchange Act .

	This Limited Power of Attorney shall be governed and construed in accordance
the laws of the State of Washington without regard to the laws that might
otherwise govern under applicable principles of conflicts of laws thereof.

	IN WITNESS WHEREOF, the undersigned has caused this Limited Power of
Attorney to be executed as of August 7, 2020.

	Signature: /s/ Susan Bobulsky
	Name: Susan Bobulsky